Navigation Links
Varian Medical Systems Reports Results for First Quarter of Fiscal Year 2013
Date:1/23/2013

%14.4%Net earnings per share – basic

$

0.87$

0.80Net earnings  per share – diluted

$

0.86$

0.79Shares used in the calculation of net earnings per share: Average shares outstanding - basic109.3112.3Average shares outstanding - diluted111.1114.4Varian Medical Systems, Inc. and SubsidiariesCondensed Consolidated Balance Sheets(In thousands)December 28,  September 28,20122012 (1)(Unaudited)AssetsCurrent assetsCash and cash equivalents

$

755,489

$

704,570Short-term investment 51,80449,709Accounts receivable, net637,473691,806Inventories499,616457,869Deferred tax assets and other283,931266,561Total current assets2,228,3132,170,515Property, plant and equipment669,119653,424Accumulated depreciation and amortization(370,586)(356,832)Property, plant and equipment, net298,533296,592Goodwill223,914222,242Other assets187,804189,377Total assets$

2,938,564

$

2,878,726Liabilities and Stockholders' EquityCurrent liabilitiesAccounts payable$

145,172

$

180,736Accrued expenses306,785336,568Deferred revenues132,881130,883Advance payments from customers396,229380,545Product warranty50,70552,799Short-term borrowings200,000155,000Total current liabilities1,231,7721,236,531Other long-term liabilities123,654126,169Long-term debt6,2506,250Total liabilities1,361,6761,368,950Stockholders' EquityCommon stock 109,322109,407Capital in excess of par value 609,246563,875Retained earnings and accumulated other comprehensive loss  858,320836,494Total stockholders' equity1,576,8881,509,776Total liabilities and stockholders' equity$

2,938,564

$

2,878,726(1)  The condensed consolidated balance sheet as of September 28, 2012 was derived from audited financial statements as of that date. 

FOR INFORMATION CONTACT:Elisha Finney (650) 424-6803

SOURCE Varian Medical Systems
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
2. Varian Medical Systems and Siemens Healthcare Announce Global Collaboration to Advance Clinical Capabilities and Offerings in Radiotherapy and Radiosurgery
3. Varian Medical Systems to Showcase Radiosurgery Technology for Non-invasive Treatment of Early Stage Inoperable Lung Cancer
4. U.S. Government Supports Phase 3 Study of Bavarian Nordics Smallpox Vaccine
5. Varian X-Ray Products Business Launches On-Line Product Finder for Customers
6. Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020
7. Cerulean Announces First Patient Dosed in Phase 2 Study of CRLX101 in Ovarian Cancer
8. Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2012
9. Researchers Discover All-Natural Weapon In The War Against Ovarian Cancer
10. Varian Medical Systems CEO Timothy E. Guertin Announces Plans to Retire; Board of Directors Names Dow R. Wilson as Successor
11. Varian Medical Systems Board of Directors Authorizes Repurchase of Additional 8 Million Shares of Stock through Calendar Year 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... N.J. , July 30, 2015  Unichem Pharmaceuticals ... recalling one lot of Hydrochlorothiazide tablets 25 mg 1000-count ... initiated as a precautionary measure due to the identification ... the product. The risk associated with ... tablet is the increased probability of experiencing Clopidogrel,s side ...
(Date:7/30/2015)... OAKS, Calif. , July 30, 2015  Amgen (NASDAQ: ... Hassan , partner and managing director of Warburg Pincus LLC, ... are pleased to welcome Fred Hassan and the ... the Amgen Board," said Robert A. Bradway , chairman ... and commitment to innovation will serve Amgen well." ...
(Date:7/30/2015)...  Growth of the U.S. nonprescription market is primarily ... users to the OTC market. Due to an increasingly ... switch activity over the next five years with several ... brands entering the market into existing categories. ... (even those with low to moderate likelihood), the market ...
Breaking Medicine Technology:Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
... Corporation (Nasdaq: DNDN ) today reported results for ... quarter ended September 30, 2010 was $20.2 million compared to ... the nine months ended September 30, 2010 was $23.1 million ... 2009.   Revenue from sales of PROVENGE® (sipuleucel-T) ...
... EMERYVILLE, Calif., Nov. 3, 2010 Onyx Pharmaceuticals, ... results for the third quarter 2010. Onyx reported non-GAAP net ... the third quarter 2010 compared to non-GAAP net income of ... period in 2009. Non-GAAP net income excludes, among other items, ...
Cached Medicine Technology:Dendreon Reports Third Quarter 2010 Financial Results 2Dendreon Reports Third Quarter 2010 Financial Results 3Dendreon Reports Third Quarter 2010 Financial Results 4Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 2Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 3Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 4Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 5Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 6Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 7Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 8Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 9Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 10
(Date:8/3/2015)... ... August 03, 2015 , ... A July 13 article from The Daily ... to Release Natural Painkiller That Can Last 'For Five Weeks'" discusses the use ... the new study showed that harvesting stem cell-rich bone marrow from the hip, known ...
(Date:8/3/2015)... ... , ... Illinois Health & Science (IHS) has completed the purchase of IBA ... of IBAM NA’s cyclotron sites and research and development facilities. , “We ... well as a large manufacturing hub in Noblesville, Indiana,” said Ken Smithmier, President and ...
(Date:8/3/2015)... Ramon, CA (PRWEB) , ... August 03, 2015 ... ... leading global insurance brokerage firm, announced today that Joe Williams has joined its ... development, sales, and delivering HUB's differentiated service model to his clients. Mr. Williams ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... with accountability for overall performance of the company’s Medicare and Federal Employee Programs ... Cambia’s strategy to deliver better health for members. In this role, Scott is ...
(Date:8/3/2015)... (PRWEB) , ... August 03, ... ... (EMSI), a leading provider of medical information, risk management and investigative services, ... evolution and direction toward focused, expert information solutions that improve business outcomes ...
Breaking Medicine News(10 mins):Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2Health News:Cambia Health Solutions Names Scott Powers President of Government Programs 2Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2
... Institute of Medical Sciences (KIMS), a leading hospital here, ... accreditation that will// help it attract patients from abroad. ... the Australian Council for Health Care Standards International (ACHSI), ... extensive, week-long survey of KIMS facilities. KIMS has become ...
... from chronic asthma do not get proper treatment and ... ,Specialists at the Johns Hopkins Children’s Center and elsewhere ... the researchers say, because preventive therapy failure leads to ... strikes and to more complications and increased risk of ...
... tiny heating device that can be inserted inside the lungs ... or nose can help treat asthma, researchers conducting its// trial ... system in which the airways constrict making it hard to ... ,Though asthma can't be cured, it can be managed with ...
... senior and well-known scientist of America’s premier medical agency ... criminal conflict of interests.// ,Dr Trey Sutherland ... drug company as consulting fees as well as providing ... is said to have received $285,000 in payment for ...
... the anti-craving drug, Naltrexone may lessen cessation-related weight gain ... quit smoking appear //to benefit more than men. As ... on gender differences in nicotine addiction and in treatment. ... of the University of Chicago have added a drug ...
... hair-growth drug finasteride, taken by millions of balding men, ... test,// the standard screening test for prostate cancer, a ... men ranging in age from 40 to 60 years ... The Lancet and is scheduled to be published after ...
Cached Medicine News:Health News:Medication Not Available On Time To Inner-city Children 2Health News:Hair-Growth Drug Artificially Lowers Psa Levels in Prostate Cancer Screening 2
... is synthesized by the parathyroid glands ... decreased extracellular calcium concentrations. PTH prevents ... decreasing calcium excretion by the kidney. ... PTH is rapidly degraded into 4 ...
... is produced in the adrenal cortex and, ... DHEA serves as a precursor in testosterone ... androgenic activity, estimated at ~10% that of ... and in adult women, DHEA is an ...
... circulating testosterone exists as unbound or free ... to SHBG with high affinity [1], while ... Both the albumin-bound and free fractions may ... testosterone action. Measurement of the free or ...
... is a 32 kDa glycoprotein secreted by ... gland [1]. The structure of human TSH ... and placental gonadotropins, consisting of an a-subunit ... hormones and a unique beta-subunit, which confers ...
Medicine Products: